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The blood–brain barrier is the main obstacle to efficient delivery of therapeutic reagents, includ-
ing viral vectors, into the central nervous system (CNS) for treating global CNS diseases. In this
study, the effects of mannitol infusions on global brain gene expression of a novel AAV vector
were examined after intravenous (iv) or intracisternal injection. Initially, a self-complementary
adeno-associated virus serotype 2 vector (scAAV) was compared to traditional single-stranded
AAV2 vector for reporter gene expression in the brain of adult mice with or without pretreatment
of an iv mannitol infusion. One to two months postinjection, analysis of vector-transduced green
fluorescent protein (GFP) expression in the brain revealed that vector delivery to the CNS via iv
injection required pretreatment with mannitol. This expression was observed only when scAAV
vectors were used. Using these conditions, transgene expression was observed in various neurons
and glial cells throughout the brain. The peripherally administered scAAV vectors also transduced
the cells in multiple somatic tissues with efficient expression in liver (20–30% of hepatocytes), but
was less efficient in other somatic tissues. Intracisternal injection of scAAV vector produced a
broad and intense transgene expression in both neurons and glial cells in the CNS of injected mice
ranging from the olfactory area to the brain stem and spinal cord. More than 50% of the Purkinje
cells in the cerebellum expressed GFP. Intravenous infusion of mannitol before intracisternal
injection of the scAAV vector enhanced the dispersion of the vector in the CNS. Further optimi-
zation of these steps combining peripheral and intracisternal scAAV gene delivery should facilitate
the development of treatments for global CNS diseases, especially diseases involving both the
somatic system and the CNS, such as lysosomal storage disorders.
INTRODUCTION
Adeno-associated virus (AAV) is a widespread parvovirus
with no known pathogenesis in human [1] and is known
to infect a wide range of human tissues. The recombinant
AAV viral vector system [2], containing less than 4% of
viral genome, has been proven to transduce various cell
types, including both neuronal and nonneuronal cells in
the mammalian central nervous system (CNS), following
direct injection into the brain [3–8]. Conventional re-
combinant AAV vectors deliver a single-stranded DNA
genome, which must be converted by host-cell-mediated
DNA synthesis to double-stranded DNA for active expres-
sion. At high multiplicities of infection, hybridization of
complementary DNA strands from separate virions may
also generate active double-stranded templates for expres-
sion [9]. This requirement for formation of duplex DNA
has proven to be an important limiting factor for AAV
vector transduction. The recently developed self-comple-
mentary AAV (scAAV) vector system provides an invalu-
able tool in AAV-mediated gene therapy studies for CNS
diseases due to its high transduction efficiency [10]. The
scAAV vector is made from constructs in which the rep-
licating DNA is less than half the length of the wtAAV
genome, thus allowing inverted repeat dimer molecules
to be encapsidated but limiting the size of the transgene.
The two halves of these molecules are complementary to
each other, and base-pair into a double-stranded hairpin
molecule once released from the capsid. Because the ki-
netics of this reaction are first order with respect to the
number of DNA molecules involved, the efficiency of
transduction (i.e., transducing units per genome-contain-
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ing particle) is independent of multiplicity of infection
and host-cell DNA synthesis
The blood–brain barrier (BBB) plays an important role
in preventing microorganisms and large molecules from
entering the CNS [11]. Likewise, it is also a major obstacle
in developing new therapies for CNS diseases because it
impedes effective delivery of therapeutic reagents, includ-
ing AAV vectors, into the CNS. Many studies have been
carried out to interrupt the BBB or have used escort sys-
tems, with the ultimate goal of enabling peripherally de-
livered therapeutic substances to cross the BBB [12–17].
Mannitol is a known blood–brain barrier interruptive
reagent. Intravenous infusion of highly concentrated
mannitol (25%) is routinely used to reduce the intracra-
nial pressure in patients with traumatic brain diseases, by
pulling fluid from the CNS by temporarily increasing vas-
cular osmotic pressure. Many human clinical studies have
been performed with intra-arterial (carotid) infusion of
mannitol or other sugar solution, to open the BBB to
enhance the CNS delivery of chemotherapeutic reagents.
Improved survival in patients with brain tumors has been
demonstrated [12,14]. Mannitol has been used in preclin-
ical studies to achieve the entrance of a wide range of
substances into brain, including enzymes, antibodies, and
viral vectors [12,18,19]. Intra-arterial infusion of manni-
tol caused no obvious BBB damage [20].
In this study, we have used a self-complementary
AAV2 vector and mannitol infusion to develop methods
of peripheral or intracisternal vector delivery, which re-
sulted in broad dispersion of AAV-mediated transgene
expression in mouse CNS and in multiple somatic tissues/
organs.
RESULTS
AAV-Mediated Transgene Expression in Mouse Brain
after Direct Microinjection
We compared the distribution of transgene expression in
adult mouse brain after direct injection of scAAV2 or
single-stranded (ss) AAV2 vectors into the thalamus or
dorsal third ventricle. Four weeks after injection, both
scAAV2 vector and ssAAV2 vector were shown to trans-
duce both neuronal and nonneuronal cells. Again, while
we observed no obvious difference in the distribution of
transgene expression in brain, green fluorescent protein
(GFP) expression from the scAAV2 vector was signifi-
cantly more intense, and involved a greater number of
cells, than that from the ssAAV2 vector (Fig. 1).
Global Distribution of AAV-Mediated Transgene
Expression in Mouse Brain after Systematic Vector
Delivery: Influence of Mannitol
In an attempt to facilitate delivery of AAV vector into the
CNS of adult mice via peripheral administration, we in-
jected the scAAV2 viral vector intravenously into adult
mice 10–20 min after an iv infusion of 25% mannitol to
disrupt the blood–brain barrier. Four to eight weeks after
injection, we carried out fluorescence microscopy to visu-
alize the AAV-mediated transgene expression on serial
Vibratome brain sections.
The iv injection of the scAAV2 vectors (4  1011 viral
particles) produced a global distribution of GFP expres-
sion in the CNS (brain and spinal cord) of all 16 mice only
when it was preceded by an iv administration of 25%
mannitol (Fig. 2). We observed no GFP expression in the
CNS of the mice injected iv with only the scAAV2-CMV-
GFP viral vector or with only the scAAV2-CMV-GFP viral
vector in 12.5% mannitol. We did not see GFP in the
brain of the mice given an iv injection of scAAV2-CMV-
GFP vectors immediately after the injection of mannitol.
We observed no transgene expression in the brains of the
mice receiving an iv injection of conventional single-
stranded AAV2 viral vector after iv injection with manni-
tol (25%).
In the mice that received the pretreatment with 25%
mannitol, we observed GFP expression from the scAAV2
vector in both neuronal and nonneuronal cells (Fig. 2),
including various neurons, some glial cells, and cells of
the choroid plexus. The transduced neurons included Pur-
kinje cells, granule cells, and stellate cells of cerebellum
and neurons in cerebral cortex, hippocampus, thalamus,
hypothalamus, brain stem, and the olfactory area. The
intensity of GFP expression varied among cells. The GFP-
expressing cells were distributed throughout the brain of
the injected mouse, although nearly 50% of them were
seen in cerebellum and brain stem. The number of brain
cells observed expressing GFP in each mouse brain was
47–58 when 4  1011 viral particles were injected intra-
venously 20 min after the iv administration of mannitol.
The GFP-expressing cells increased to 58–132 when intra-
venous injection of the vector was conducted at 15 min
after iv infusion of mannitol and to over 500 when the
vector was delivered at 10 min after mannitol was admin-
istered.
Broad Dispersion of AAV Transgene Expression in the
Brain after Intracisternal Injection of scAAV2 Vector
We carried out intracisternal injection of scAAV vector in
4- to 6-week-old normal mice to study the efficiency of
CNS vector delivery with this approach. We compared the
AAV-mediated GFP gene expression in mouse brains in
the intracisternally injected mice with (n  8) or without
(n  4) prior iv infusion of mannitol, to determine
whether dispersion of the AAV vector would be affected.
Intracisternal delivery resulted in a broad spread of the
scAAV2 vector in mouse CNS (Fig. 3). We observed
broader dispersion and more intense GFP expression in
the CNS of the mice infused iv with mannitol 15–20 min
before intracisternal injection of AAV vector, compared to
that in the CNS of the mice that were not pretreated (Fig.
3). In the mice intracisternally injected with scAAV2 vec-
tor, we observed transgene expression in neuronal and
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FIG. 1. Comparison of AAV-mediated
transgene expression in mouse brain
by direct injection. Self-complemen-
tary AAV2 vector scAAV-CMV-GFP and
conventional AAV2 vector ssAAV-CMV-
GFP (1  108/l) were delivered into
the dorsal third ventricle (5 l/injec-
tion/mouse) of normal adult mice (2–3
months of age) by direct microinjec-
tion. Transverse Vibratome sections of
whole brain sample were analyzed 4
weeks after infusion. Sections at
bregma 1.58. (a) scAAV2: self-com-
plementary AAV2 vector. (b) ssAAV2:
conventional AAV2 vector. 1, Cerebral
cortex; 2, hippocampus; arrow, dorsal
third ventricle.
FIG. 2. AAV-mediated transgene expres-
sion in mouse brain after intravenous injec-
tion. Self-complementary AAV2 vectors (4
 1011 in 200 l PBS) were delivered into
adult mice (2–3 months of age) after an iv
infusion of 200 l mannitol (25%). Four or
eight weeks after infusion, multiple tissue
samples were collected after transcardial
perfusion. Transverse sections (50 m) of
entire brain were obtained using a Vi-
bratome for fluorescence microscopy. (a) A
neuron in the thalamus. (b) Neurons in
brain stem. (c) A Purkinje cell in the cere-
bellum. (d) A glial cell in cerebral cortex
(see arrows). Bar, 100 m.
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nonneuronal cells in many areas throughout the mouse
brain, including olfactory, hippocampus, striatum, corpus
callosum, thalamus, hypothalamus, cerebral cortex, cere-
bella, and brain stem (Fig. 3). We saw more intensive GFP
expression in cerebellum and brain stem, compared to
that in the other brain areas. Purkinje cells (more than
50%) and small cells in the molecular layer and granule
layer were efficiently transduced (Fig. 3). We observed
FIG. 3. AAV-mediated GFP expression in
mouse brain after intracisternal injection.
Self-complementary AAV2 vector (4 
1010 viral particles in 15 l PBS) was deliv-
ered into the posterior cistern of mice (4–6
weeks of age) 20 min after an iv infusion of
200 l mannitol (25%). Transverse sec-
tions (50 m) of whole brain were pre-
pared for fluorescence microscopy 4 weeks
after infusion, using the stereotaxic coordi-
nates of Franklin and Paxinos. (a–e) Bar,
1.0 mm. (f–l) Bar, 100 m. (a) Bregma
3.08 mm, (b) bregma 0.34 mm, (c)
bregma 1.34 mm, (d) bregma 5.52
mm. (e) A brain section (bregma 5.68
mm) of a mouse intracisternally injected
with scAAV 2 vector, without pretreatment
with mannitol. (f) Bregma 2.80, olfactory
bulb; (g) bregma 1.82, arrow—hip-
pocampus; (h) bregma 1.34, arrow—
dorsal third ventricle; (i) cerebellum, ar-
rows—Purkinje cells; (j) brain stem,
arrow—fourth ventricle (bregma 5.40);
(k) cervical spinal cord (ventral white mat-
ter, longitudinal section). l, Cervical spinal
cord (half longitudinal section); bottom,
lateral surface; top, middle line.
FIG. 4. AAV-mediated transduction in
mouse liver by intravenous delivery.
Self-complementary AAV2 vectors
(scAAV-CMV-GFP) or conventional AAV
vectors (ssAAV-CMV-GFP) (4  1011 in
200 l PBS) were delivered into adult
mice (2–3 months of age) 20–30 min
after an iv infusion of 200 l mannitol
(25%). Cryostat sections (30 m) of
liver samples were analyzed for GFP
expression 8 weeks after infusion. (a)
scAAV2: self-complementary AAV 2
vectors. (b) ssAAV2: conventional AAV
vectors.
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GFP-positive projections throughout the brain and spinal
cord (Fig. 3). More cells were seen to express GFP in the
areas with cerebral–spinal fluid contact, i.e., the cells sur-
rounding the ventricle system. Only sporadic cells, in
cerebral cortex and spinal cord, expressed GFP. We ob-
served no obvious sign of toxicological reaction or cell
damage in the brains of injected mice and the animals
appeared healthy during the period of the experiments.
Intracisternal injection of ssAAV vector resulted in a
similar distribution of GFP expression in mouse brains but
the intensity of the transgene expression was much lower
compared to that mediated by scAAV vector (Fig. 3e).
AAV-Mediated Transduction in Peripheral Tissues
after iv Administration
We also surveyed the distribution of AAV-mediated trans-
duction in multiple somatic tissues of mice, with or with-
out the iv injection of mannitol. We observed no obvious
difference in the number of cells transduced, or in the
intensity of GFP expression, in somatic tissues with or
without mannitol pretreatment.
In the livers of mice injected iv with 4  1011 vector
particles of scAAV2-CMV-GFP, we observed transgene ex-
pression in 20–30% of hepatocytes (Fig. 4). We saw lower
numbers of GFP-positive cells in other somatic tissues:
3% in heart, lung, adipose tissue, and spleen; 1% in
intestine and skeletal muscle (data not shown); and only
occasionally in kidney. Intravenous injection of the
ssAAV vectors resulted in visible GFP expression in only
1–2% of hepatocytes in liver (Fig. 4), but not in other
tissues. We observed no apparent cell damage in the tis-
sues of animals injected with either vector.
DISCUSSION
A recently developed scAAV vector, carrying a dimeric
genome, has a much higher transduction efficiency than
the conventional rAAV vector, which contains only a
single-copy, single-stranded genome [10]. We have taken
advantage of the transduction potency of the scAAV viral
vector system to map and optimize vector distribution in
the CNS and peripheral tissues. Because of this greater
sensitivity we were able to demonstrate that pretreatment
with an iv infusion of mannitol facilitated entry of pe-
ripherally delivered AAV vector into the CNS, by presum-
ably interrupting the blood–brain barrier. Intracisternal
administration of AAV vector resulted in broad distribu-
tion of transgene expression in the mouse CNS, which
was enhanced by iv infusion of mannitol prior to the
vector injection.
Using the scAAV2 viral vector, a global distribution of
AAV-mediated transgene expression was achieved in
mouse brain by systemic delivery of the vectors into ani-
mals pretreated with an intravenous infusion of 25% of
mannitol. This was not observed using ssAAV vectors,
thus illustrating the utility of scAAV in biodistribution
studies. Because these vectors are transduced independent
of cellular DNA synthesis, the scAAV vectors are not lim-
ited by the ability of the recipient cell to replicate DNA or
convert single-stranded AAV genome to duplex or by the
stability of the single-stranded genomes. While this may
not translate directly to the efficiency of transduction
ultimately achieved with the ssAAV vector, parameters
such as cell and tissue tropism using different AAV sero-
types or methodologies of vector delivery can be reliably
established.
Previous studies have shown the access of substances
to the CNS in human and experimental animals after
intra-arterial administration of mannitol [12]. This study
demonstrated that an iv infusion of mannitol disrupted
the blood–brain barrier to a degree that allowed periph-
erally delivered scAAV viral vectors to enter the CNS and
transduce both neuronal and nonneuronal cells through-
out the brain. However, the disruption of the blood–brain
barrier by mannitol is temporary and reversible, and the
BBB can rapidly regain its integrity through the physio-
logical rearrangement of the body fluid. Therefore, the
timing of AAV vector delivery after the infusion of man-
nitol is critical to the efficiency of the CNS entry. The
optimal timing is unclear for opening of the BBB, but the
clinical effects of mannitol occur typically within 20–30
min of iv injection in humans. Previous studies showed
that by intra-arterial administration of mannitol through
the carotid artery, the peak opening of the BBB was 5 min
after infusion [27] and the opening lasted for 20–30 min
[12]. This study showed a 10-fold increase in the number
of the transgene expressing cells, when the time between
the iv infusion of AAV vector and the iv administration of
mannitol was decreased from 20 to 10 min. Additional
time-course studies will be needed to determine the opti-
mal window for iv injection of AAV vectors, after iv infu-
sion of mannitol, to achieve the highest level of transduc-
tion in the CNS by systemic delivery.
Using intracisternal injection of the scAAV2 vector,
this study demonstrated a high efficiency and broad dis-
tribution of transgene expression in mouse CNS, an effect
that was enhanced by systemic mannitol administration.
The pretreatment with mannitol may facilitate the diffu-
sion of the vectors intrastitially through brain tissue
and/or increase the entry into cells, due to the relative
dehydration of the brain by mannitol. The intracister-
nally delivered AAV vectors appeared to spread exten-
sively in the CNS, mainly through the circulation of ce-
rebral spinal fluid (CSF). This route of administration may
therefore provide a great potential for AAV-mediated CNS
gene delivery. In addition, intracisternal injection allows
us to deliver the vectors safely to mouse CNS in a rela-
tively large volume, compared to intraventricular injec-
tion, since the physical characteristics of the injection site
provide higher buffer capacity for the pressure increase in
the system. Intracisternal injection may thus contribute
significantly to the development of AAV gene therapies
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for global CNS diseases. The translation of this technique
to human clinical trials at this time may be limited, since
the volume of the intracisternal injection was about 25%
of the total volume of CSF in adult mice. Although the use
of mannitol may reduce the intracranial volume and pos-
sibly improve vector delivery, feasibility studies in small
and large animals are needed prior to considering clinical
trials in humans.
Finally, this study also demonstrated a widespread
transgene expression in the peripheral system after iv
infusion with AAV, although differences in transduction
efficiency among organs were observed. These differences
may be due to many factors, including the abundance of
blood supply to the organ, the level of AAV2 receptor
expression on the cell surfaces in different tissues, differ-
ent subcellular trafficking pathways in the different cell
types, or differential activity of the cytomegalovirus
(CMV) promoter in each cell type. Importantly, in con-
trast to the brain tissue, there was no obvious difference in
the transduction efficiency in somatic tissues of mice in
the presence or absence of mannitol. We therefore antic-
ipate that administration of mannitol has little or no
direct effect on the efficiency of AAV-mediated transduc-
tion in peripheral tissues. The wide tropism of AAV2 to
different organs and tissues after iv injection suggests the
potential of AAV gene delivery for diseases involving mul-
tiple organs/tissues, such as lysosomal storage disorders.
Such treatments may be further enhanced through mul-
tiple applications of different AAV serotypes carrying the
same transgene, thus maximizing the numbers and types
of cells genetically corrected. Since intracisternal admin-
istration leads to wide dispersion of AAV-mediated trans-
duction through the CNS, combining intravenous and
intracisternal delivery of AAV vector with mannitol pre-
treatment could significantly enhance the therapeutic ef-
fects for diseases with both CNS and somatic involve-
ment.
MATERIALS AND METHODS
AAV viral vectors. A recently constructed AAV2 vector plasmid, pHpa-
Trs-SK (manuscript in preparation), was used to produce the self-comple-
mentary AAV2 viral vector (scAAV2-CMV-GFP) containing a human CMV
promoter and an enhanced GFP gene. This construct produces only
dimeric inverted repeat genomes during replication since the terminal
resolution site is deleted from one of the terminal repeats, inactivating it
as an origin of replication. Vectors prepared using this mutant background
contain greater than 90% scAAV vector genomes. A control AAV2 vector
plasmid, pTRUF-GFP, was used to produce the conventional AAV2 viral
vector (ssAAV-CMV-GFP), also expressing GFP and driven by a CMV pro-
moter.
The recombinant AAV2 viral vectors were produced in 293 cells using
three-plasmid cotransfection, and purified following previously published
methods [21,22] by the Vector Core Facility, Gene Therapy Center, Uni-
versity of North Carolina at Chapel Hill.
Animals. Normal C57 mice (2–3 months of age) used in this study were
bred and maintained in the Laboratory Animal Facility of the University of
North Carolina at Chapel Hill. All the procedures were approved by IACUC
at the university. All care and procedures were in accordance with the
Guide for the Care and Use of Laboratory Animals (NHHS Publication No.
(NIH) 85-23).
Direct microinjection of AAV vectors into mouse brain. scAAV2-CMV-
GFP and ssAAV2-CMV-GFP viral vectors were delivered into the thalamus
or the dorsal third ventricle of normal mice, 2–3 months of age, by direct
microinjection. The stereotaxic (KOPF) microinjection was carried out
following previously published techniques [3,23], using coordinates from
the mouse brain atlas of Franklin and Paxinos [24]. The mice were anes-
thetized with 2.5% Avertin (0.38–0.43 mg/g body weight) before the
infusion. Two microliters of AAV viral vectors (1  108viral particles/l)
was infused into the right thalamus at a rate of 0.1 l/min and 5 l into the
dorsal third ventricle at a rate of 0.5 l/min, one injection per site per
mouse, four mice per experimental group.
Four weeks after infusion, the animals were anesthetized with 2.5%
Avertin and then perfused transcardially with cold 0.1 M phosphate-
buffered saline (PBS) (pH 7.4), followed by 4% paraformaldehyde in phos-
phate buffer (0.1 M, pH 7.4). The entire mouse brain samples were col-
lected and fixed at 4°C in 4% paraformaldehyde for fluorescence
microscopy.
Intracisternal injection. Intracisternal injection was conducted in normal
mice (4–6 weeks of age), four mice per experimental group, following
previously published procedures [25,26]. The animals were anesthetized
with intraperitoneal injection of 2.5% Avertin (0.38–0.43 mg/g body
weight). Fifteen microliters of scAAV or ssAAV vector, 3  1010 viral
particles in PBS, was rapidly injected (2 s) into the posterior cistern of
each mouse, 15–20 min after an iv infusion (2 min) of 200 l mannitol
(25%) or without pretreatment with mannitol.
The mice were perfused transcardially as described above, 4 weeks
postinjection. The brain and spinal cord samples were collected and fixed
in 4% paraformaldehyde at 4°C for fluorescence microscopy.
Peripheral delivery of AAV viral vectors. AAV vectors, 4  1011 in PBS (pH
7.4), were delivered into adult male mice (2–3 months of age) by intrave-
nous injection through the tail vein. The volume of each injection was 200
l (about 10 l/g body weight) over a period of 2 min.
The injection was carried out as follows. The animals were anesthe-
tized by intraperitoneal injection of 2.5% Avertin (0.38–0.43 mg/g body
weight) before iv infusion of a dose (200 l) of mannitol (25%, for iv use
only, Abbott Laboratories, NDC0074-4031-01) through the tail vein into
each mouse over a period of 2 min. Ten to twenty minutes after the
injection of mannitol, each mouse was given AAV2 vectors in 200 l of
PBS intravenously.
Controls included the following mice: iv injected with only the self-
complementary AAV2 vectors, iv injected with scAAV vectors immediately
after injection of a dose of mannitol, iv injected with mannitol followed
by conventional AAV2 vectors, and iv injection of the scAAV2 vector in
12.5% mannitol and uninjected animals. Each experimental group in-
cluded two to four mice.
Four or eight weeks after the injection, the animals were perfused
transcardially as described above. The entire brain, as well as multiple
somatic tissue samples, including liver, kidney, spleen, heart, lung, intes-
tine, skeletal muscle, and fat tissue, were collected and fixed in 4% para-
formaldehyde at 4°C for fluorescence microscopy.
Fluorescence microscopy. Fluorescence microscopy was carried out to vi-
sualize the AAV-mediated transgene expression. After being fixed in 4%
paraformaldehyde at 4°C overnight, serial transverse brain sections (50
m, 150–180 sections/brain) and longitudinal spinal cord sections (50
m) were obtained using a Vibratome. Other tissue samples were embed-
ded in OCT compound and frozen on dry ice before being sectioned (30
m) with a cryostat. The sections were then mounted on slides and
visualized with a fluorescence microscope.
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